about
Clinical significance of T cell metabolic reprogramming in cancerCholine Metabolism Alteration: A Focus on Ovarian CancerEvolving Insights on Metabolism, Autophagy, and Epigenetics in Liver MyofibroblastsMetabolomics in rheumatic diseases: desperately seeking biomarkersCancer Metabolism: A Modeling PerspectiveA novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosisCancer Metabolism and Drug ResistanceMolecular magnetic resonance imaging in cancerOvarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reductionPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerChloroquine and hydroxychloroquine for cancer therapyAutophagy in malignant transformation and cancer progressionA roadmap for interpreting (13)C metabolite labeling patterns from cellsTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyRedox control of glutamine utilization in cancerAntagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolismHeterogeneity of glycolysis in cancers and therapeutic opportunities.Caveolin-1 in the regulation of cell metabolism: a cancer perspectiveUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyROS homeostasis and metabolism: a critical liaison for cancer therapyThe role of Fatty Acid oxidation in the metabolic reprograming of activated t-cellsMetabolic control of cancer cell stemness: Lessons from iPS cellsTrial Watch: Proteasomal inhibitors for anticancer therapyEvidence of cancer-promoting roles for AMPK and related kinasesCell biology. Metabolic control of cell deathNon-thermal plasma with 2-deoxy-D-glucose synergistically induces cell death by targeting glycolysis in blood cancer cellsMethionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6.An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain CancersTrial Watch: Toll-like receptor agonists in oncological indications.Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step.Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment.Metabolic control of autophagyTrial Watch: Peptide-based anticancer vaccines.Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells.Attacking the supply wagons to starve cancer cells to death.TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseasesLarge-scale identification and analysis of suppressive drug interactions.Tumor mechanics and metabolic dysfunction.Metabolic phenotypes in pancreatic cancer.
P2860
Q26741974-AFA41497-E705-43DC-AE1C-7A4246590DB9Q26742116-0124E51A-32CF-4143-A165-8A5F5A6D55C5Q26745566-DACA8F3A-8674-4556-A199-2E92154FA0C0Q26765005-EA600117-D799-4062-A6F3-BC1C57B4CF3FQ26770819-D6271900-7CF0-4A82-B211-1149081422ACQ26774351-23EA879E-D1B7-4583-ABC2-AC91ED562181Q26782042-B92B4E6C-ED02-4FCA-A2D0-621DE62A12E6Q26782151-E6B78C6B-D05F-4F94-9A09-6CDEFEC938E8Q26786610-05CF25E9-031F-4FD4-8AFA-7847559FC57EQ26795466-115DB1EE-FDDD-44E6-9D78-2D4474A593DCQ26827797-36801D8A-A4AE-4318-9AC6-1CEB5C616EBDQ27000191-EB669657-7FDF-41B5-A312-274172B8F738Q27003299-1B894A2D-3355-4003-9903-36124E29FF48Q27004011-E2E17896-9041-4188-A0D0-619C6BC1A2CCQ27005615-46F8F96C-84C4-4201-B52D-BEED543F331CQ27316754-E75B9881-C766-4AB7-BED0-9C4CA5440919Q27693375-D730722A-2254-41DE-AA69-375628900292Q28072525-2FD910D0-4905-468A-83FC-921F2DF36231Q28076097-A0761025-425F-457B-85BD-BD777C588B6EQ28080316-882F9AB3-3698-491E-AD1B-7195C4F69951Q28080686-A7BAA736-89EC-4CF9-9E08-7CC75FBC98AEQ28081608-2FE16E95-C767-4272-94BC-3FFEA5D36DDCQ28082910-A33DF2FF-301A-4191-8745-041CFFFA58CCQ28083964-472FB7D6-E9CD-461F-94E8-35470D910FA3Q28397089-DE377A43-DF1B-4072-BF61-38BCD3D14DA8Q33559623-8174C63E-1FC2-45D1-8039-B743110177C4Q33775244-1970D5E5-63C9-4767-8D09-1FF3D6DDFA1FQ33822099-91E6D936-7C4C-40D6-92BA-441F75486F35Q33878578-0B932660-D88B-4E8B-8CFF-FC4B74E58E7EQ33987684-EE1726EC-4AD9-4A7D-9241-F5AC2D11B62AQ34007740-E3BD4B97-A65D-4C52-AA15-06DAFC28EEC8Q34452291-F12653F6-F337-4A38-B5F8-F9BE7950E533Q34483345-85AE444C-4DFC-40BC-B721-DB5F502CCBD0Q34483548-F69AA858-CAAF-4601-94C0-F8B1965288B0Q34516773-6AB2B12C-2307-47FE-A29C-74214D2B2561Q34539146-6408E22D-E4E6-44E6-9AA2-8442A65AD6F9Q34657382-7048579C-C539-45AF-A13E-752FDFEBDA88Q34799147-72F0D88E-BA83-443A-9553-43012FC2A65AQ35117423-79EE2452-0594-413E-8E8E-4C1563491378Q35125169-9FF83613-9512-489E-8690-93929BD11D96
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Metabolic targets for cancer therapy.
@en
Metabolic targets for cancer therapy.
@nl
type
label
Metabolic targets for cancer therapy.
@en
Metabolic targets for cancer therapy.
@nl
prefLabel
Metabolic targets for cancer therapy.
@en
Metabolic targets for cancer therapy.
@nl
P50
P356
P1476
Metabolic targets for cancer therapy.
@en
P2093
Matthew G Vander Heiden
P2888
P304
P356
10.1038/NRD4145
P577
2013-10-11T00:00:00Z
P5875
P6179
1015392659